Kornimate/medical-research-clean huggingface dataset:
study of intra- and interpersonal multimodal synchronizations in a social interaction in individuals with a diagnosis of schizophrenia.

Conditions: Schizophrenia

Summary: the aim of this study is to precisely identify deficits in intra- and interpersonal multimodal synchronizations during social interaction in individuals with schizophrenia (isz). during a social interaction, individuals use both visual and auditory channels to construct their discourse. the auditory channel encompasses the semantics and prosody of the speech, while the visual channel describes the entirety of non-verbal gestures (e.g., facial expressions, body movements). prosody and non-verbal gestures are essential elements for the speaker. by accompanying speech, they contribute to the planning and conceptualization of the utterance and enhance its communicative power. for the listener, prosody and non-verbal gestures are also used to provide sensory feedback to the speaker. several studies have shown the existence of intrapersonal and interpersonal synchronizations of prosody and non-verbal gestures during interaction. these synchronizations are associated with numerous social benefits (e.g., increased mutual appreciation and quality of interaction). however, certain mental disorders, such as schizophrenia, exhibit deficits in non-verbal behaviors that can impair these synchronizations and the associated social benefits. we hypothetized that interaction with individuals with a daignosis of schizophrenia will be associated with deficits in intra and interpersonal synchronization.

this study includes a pre-inclusion interview followed by a visit to the university hospital (chu) lasting about 2 hours (including a break). during the visit, the patient participates in an experimental protocol consisting of two parts. in the first part, the patient will be paired with an interaction partner, and the two participants will engage in four distinct conversational tasks, including getting to know each other, free discussions, structured dialogues, and emotional interactions. in the second part, the participants will answer several questionnaires and perform neuropsychological tests in collaboration with an experimenter

Eligibility criteria:
individuals with a diagnosis of schizophrenia : inclusion criteria: * diagnosis of schizophrenia according to the dsm-v * being able to read, speak and understand french * giving eclaired consent exclusion criteria: * history of head trauma * history of neurological conditions (epilespsy, multiple sclerosis, parkinson's disease, amyotrophic lateral sclerosis, huntington's disease, stroke) * substance use * pregnant women healthy controls : inclusion criteria: * being able to read, speak and understand french * giving eclaired consent exclusion criteria: * diagnosis of psychosis * history of head trauma * history of neurological conditions (epilespsy, multiple sclerosis, parkinson's disease, amyotrophic lateral sclerosis, huntington's disease, stroke) * substance use * pregnant women

Keywords: social interaction interpersonal synchronization
a study of pf-04171327 in the treatment of the signs and symptoms of rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study will investigate the safety and efficacy of an investigational drug, pf-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. this study will also look at the response of chemical and biological markers in rheumatoid arthritis patients. lastly, this study will measure the pk (amount of drug in the blood) of methotrexate while patients may be taking pf-04171327.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age, diagnosed with rheumatoid arthritis for a minimum duration of 3 months * on stable dose of methotrexate for at least 6 weeks prior to screening * patient must have minimum disease activity level of ≥ 6 tender/painful joints, ≥ 6 swollen joints and crp ≥ 0.7 mg/dl * not currently receiving steroid medication exclusion criteria: * pregnant or nursing women * patients that have active infections, tb, hiv and/or hepatitis b or c * patients that have a history of intolerance or significant adverse effects with the use of glucocorticoids

Keywords: rheumatoid arthritis glucocorticoids prednisone
safety and antiviral activity study of clevudine 30 mg qd in patient with chronic hbv

Conditions: Hepatitis B

Summary: the purpose of this study is to determine safety and efficacy of 30 mg daily dose of clevudine (l-fmau) at 24 weeks of treatment in patients with chronic hbv.


Eligibility criteria:
inclusion criteria: 1. patients who were between 18 and 60, inclusive. 2. patients with hbv dna ³1 x 106 copies/ml within 30 days of baseline. 3. patients who were documented to be hbsag positive for \> 6 months. (the documentation of positive hbsag for the previous 6 months included previous laboratory reports of hbsag positive or hbeag positive at least 6 month ago or igm anti-hbc negative and igg anti-hbc positive at screening). 4. patients who were hbeag positive. 5. patients with alt levels which were in the range of ≥1.2 and \< 15 times of the upper limit of normal (x uln) and bilirubin levels less than 2.0 mg/dl, prothrombin time of less than 1.7 (inr), and a serum albumin level of at least 3.5 g/dl. 6. women of child bearing potential with a negative serum (β-hcg) pregnancy test taken within 14 days of starting therapy. 7. patients who were able to give written informed consent prior to study start and to comply with the study requirements. exclusion criteria: 1. patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy. 2. patients previously treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for hbv infection. 3. previous treatment with interferon that had ended less than 6 months prior to the screening visit. 4. patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. 5. patients co-infected with hcv, hdv or hiv. 6. patients with clinical evidence of liver mass or with alpha-fetoprotein \> 50 ng/ml 7. patients who were pregnant or breast-feeding. 8. patients who were unwilling to use an "effective" method of contraception during the treatment and for up to 3 months after cessation of therapy. for males, condoms should be used. females had to be surgically sterile (via hysterectomy or bilateral tubal ligation) or post-menopausal or using at least medically acceptable barrier method of contraception ( i.e. iud, barrier methods with spermicide or abstinence) 9. patients with a clinically relevant history of abuse of alcohol or drugs. 10. patients with a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, biliary diseases except asymptomatic gb stone, neurological, cardiovascular, oncologic or allergic disease. the patients with a benign tumor were excluded if judged by an investigator that the continuation of study would be interfered by benign tumor. 11. patients with creatinine clearance less than 60ml/min as estimated by the following formula : (140-age in years) (body weight \[kg\]) (72) (serum creatinine \[mg/dl\]) \[note: multiply estimates by 0.85 for women\] patients who were found to have ymdd hbv dna polymerase mutation at baseline were to be excluded from the overall efficacy evaluation and analyzed separately. they were to be included in the overall safety evaluation.
physical exercise and energy balance

Conditions: Physical Activity

Summary: this study is a randomized controlled trial, designed to evaluate the effect of structured physical exercise sessions on the spontaneous physical activity energy expenditure and caloric intake in overweight adults. the design employs a parallel three-group experimental arms: (1) a moderate exercise group (meg); (2) a vigorous exercise group (veg); and a control group (cg) without physical exercise sessions.


Eligibility criteria:
inclusion criteria: 1. male 2. overweight exclusion criteria: 1. diabetes mellitus 2. cardiovascular diseases 3. musculoskeletal injuries

Keywords: spontaneous physical activity caloric intake
correlation between the changes of retinal structure and function and ischemic stroke

Conditions: Ischemic Stroke

Summary: ischemic stroke is the most common type of stroke, accounting for 60%-80% of all types of strokes, and is one of the leading global causes of death and severe disability. in the risk factors of stroke, carotid atherosclerosis have higher incidence.as the only visible microvessels in vivo, retinal can provides an accurate window into cerebrovascular and systemic vascular conditions. optical coherence tomography angiography (octa) and electroretinogram (erg) can be used to quantitatively analyze the retinal structure and function in patients with ischemic stroke, and find out the valuable parameters. electroencephalogram(eeg) can collect the electrical activity of cerebral cortex in patients with ischemic stroke and find the correlation between eeg and erg. finally, it is of great significance to establish a non-invasive, more objective, convenient and safe risk prediction model for stroke in combination with carotid atherosclerosis, retinal structural and functional parameters and eeg.

firstly, this study will cross sectional analyze the retinal structure and function of patients with ischemic stroke to find the closely related parameters. secondly, based on the results of cross section analysis, a cohort study will be established to build a risk prediction model for stroke combining carotid atherosclerosis, retinal structure and function parameters and eeg.

Eligibility criteria:
inclusion criteria: * patients with ischemic stroke exclusion criteria: * refractive interstitial turbidity affect the examination results * any retinal diseases * other causes of ischemic stroke (cardiogenic embolism, dissection aneurysm, hemagglutination disorder, polycythemia, vasculitis, vascular malformation, etc.) * fails to complete an ophthalmic examination or the follow-up

Keywords: ischemic stroke retinal
treatment of shoulder osteoarthritis

Conditions: Chronic Shoulder Pain

Summary: the purpose of this study is to learn if pain can be relieved by delivering small amounts of electricity ("electrical stimulation") to the nerves relaying sensory information to the shoulder. this study will use a device called sprint pns system. pns stands for peripheral nerve stimulation. this device is cleared by the fda for up to 60 days of use for relief of chronic or acute pain.


Eligibility criteria:
key inclusion criteria: * diagnosed with degenerative changes within the shoulder complex key exclusion criteria: * pain exclusively in the anterior aspect of the shoulder * opioids for any condition other than shoulder pain * other implanted electronic device
connecting contact lenses and digital technology

Conditions: Asthenopia; Contact Lenses; Ocular Accommodation; Convergence, Excess

Summary: this study seeks to address whether or not different types of daily disposable soft contact lenses may be a beneficial option for patients complaining of eye strain and visual discomfort while using digital devices.

this was a prospective, single site, randomized, double-masked, crossover pilot study. subjects were randomized to begin with either multifocal or single vision distance contact lenses. the lenses used in this study were the 1-day acuvue (av) moist spherical single-vision soft contact lenses (sscl) in the 8.5 base curve and the 1-day av moist multifocal (mfscl) in the low add (etafilcon a, 58% water content). the preferred viewing distance on digital devices for a similar age group to our study was 63 cm which would require a near add of +1.59d. a low addition (add) yielding up to +1.25d was selected to provide an intermediate near addition without compromising distance vision as much as would be expected with higher add powers. the multifocal lens utilizes an aspheric center-near design. subjects wore the lenses on a daily wear, daily disposable schedule. following one week (± 2 days) of lens wear, subjects were evaluated and the alternate lenses dispensed. adverse events were collected and assessed at each study visit.

Eligibility criteria:
inclusion criteria: 1. 18 to 35 years of age 2. spectacle prescription of -0.75 to -6.00 d sphere with no more than 0.75 diopters of refractive cylinder 3. current single-vision soft contact lens wearer 4. monocular acuity of 20/25 or better in each eye (snellen) 5. self-reported minimum of 6 hours a day on digital devices 6. self-reported complaint of eyestrain on digital devices 7. no ocular pathology and/or history of eye surgery 8. no history of strabismus or strabismus surgery 9. no gas permeable lens wear for at least 3 months 10. subjects may not be optometrists, opticians or optometry students exclusion criteria: 1. corneal staining, blepharitis and/or meibomian gland dysfunction (mgd) worse than grade 2 using the efron grading scale 2. negative relative accommodation (nra) less than +1.50 d 3. exophoria at near \> 6 prism diopters10 4. vertical phoria \> 1 prism diopter 5. presence of tropia 6. response of 3 or higher on question 2b of the contact lens dry eye questionnaire- 8 (cldeq-8) 7. unacceptable contact lens fit (i.e. substantially decentered, excessive movement)
study of long term safety and clinical outcomes of idursulfase it and elaprase treatment in pediatric participants who have completed study hgt-hit-094

Conditions: Hunter Syndrome

Summary: this extension study will allow participants that completed study hgt-hit-094 to continue receiving elaprase treatment in conjunction with idursulfase it or to continue receiving elaprase treatment and begin concurrent it treatment for those that did not receive idursulfase it treatment in study hgt-hit-094.


Eligibility criteria:
inclusion criteria: * participants must have completed visit week 52 assessments in study hgt-hit-094 (nct02055118). * the participant's parent(s) or legally authorized guardian(s) must have voluntarily signed an institutional review board (irb)/independent ethics committee (iec) approved informed consent form after all relevant aspects of the study have been explained and discussed. consent of the participant's parent(s) or legally authorized guardian(s) and the participant's consent/assent, as relevant, must be obtained. * the participant has continued to receive elaprase on a regular basis in study hgt-hit-094 (nct02055118). exclusion criteria: * the participant has experienced, in the opinion of the investigator, a safety or medical issue that contraindicates treatment with idursulfase-it, including, but not limited to, uncontrolled seizure disorder, bleeding disorder, and clinically relevant hypertension. * the participant has a known hypersensitivity to any of the components of idursulfase-it. * the participant has clinically relevant intracranial hypertension. * the participant is enrolled in another clinical study, other than hgt-hit-094 (nct02055118), that involves clinical investigations or use of any investigational product (drug or \[intrathecal/spinal\] device) within 30 days prior to study enrollment or at any time during the study. * the participant has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to compromised airways or other conditions. * the participant has a condition that is contraindicated as described in the soph-a-port® mini s, implantable access port, spinal, mini unattached, with guidewire (soph-a-port mini s) intrathecal drug delivery device (iddd) instructions for use, including: 1. the participant has had, or may have, an allergic reaction to the materials of construction of the soph-a-port mini s device. 2. the participant's body size is too small to support the size of the soph-a-port mini s access port, as judged by the investigator. 3. the participant's drug therapy requires substances known to be incompatible with the materials of construction. 4. the participant has a known or suspected local or general infection. 5. the participant is at risk of abnormal bleeding due to a medical condition or therapy. 6. the participant has 1 or more spinal abnormalities that could complicate safe implantation or fixation. 7. the participant has a functioning csf shunt device. 8. the participant has shown an intolerance to an implanted device.
osteochondritis dissecans of the knee

Conditions: Osteochondritis Dissecans; Juvenile Osteochondritis Dissecans

Summary: osteochondritis dissecans is a relatively common...


Eligibility criteria:
inclusion criteria: * osteochondritis dissecans diagnosis code (icd-8 to -10) in the medical records of kuh * knee ocd verified from the medical records exclusion criteria: -any other medical condition

Keywords: osteochondritis dissecans juvenile osteochondritis dissecans knee osteochondral outcome
non-invasive brain stimulation for auditory verbal hallucinations in schizophrenia

Conditions: Auditory Verbal Hallucinations; Schizophrenia

Summary: the current study investigates the basic principles that underlie the efficacy of transcranial direct current stimulation for chronic auditory verbal hallucinations in schizophrenia in a multimodal design.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * chronic auditory verbal hallucinations * right-handed exclusion criteria: * drug abuse other than nicotine * severe cognitive deficits * severe medical conditions * severe neurological disorders * severe microangiopathy * history of electroconvulsive therapy * pregnancy or lactation
x-ray-free protocol for pectus deformities based on magnetic resonance 1 imaging and a low-cost portable three-dimensional scanning device

Conditions: Pectus Deformity

Summary: pectus excavatum (pe) and pectus carinatum (pc) are the most frequent chest wall deformities in humans. they are usually clinically recognized in early childhood or adolescence, with aggravation during the pubertal growth spurt. pe is a depression of the anterior chest wall, most frequently involving the lower sternum. in this study we use simultaneously compared chest ct, mri, and 3d scanning fro both pe and pc assessment . the aim of this study is to compare a standard protocol using chest ct to a non-irradiant protocol with 3d scanning and mri. the primary endpoint was to assess the inter observer concordance and the correlation between the hi (haller index) evaluated with mri and the ehi (external haller index) evaluated with 3d scanning. the secondary endpoints were to assess the concordance with chest ct the variation of the hi evaluated in inspiration and expiration with mri and also the correction index (ci) between chest ct and mri in the pe group, .


Eligibility criteria:
inclusion criteria: * children (\< 18 years of age) * with a pectus deformity * recent (within the past month) chest ct, cardiothoracic mri, and 3d scanning data were available. exclusion criteria: -
a 14-item questionnaire regarding career preferences among chinese medical undergraduate students.

Conditions: Career Burnout; Student Burnout

Summary: this survey was performed as part of a career choice research program for undergraduate medical students. all students received a qr code link to the survey as part of their course work.

this survey was performed as part of a career choice research program for undergraduate medical students. all students received a qr code link to the survey as part of their course work, although participation was voluntary and anonymous. all participants received verbal and online explanations of the questionnaire and were informed that informed consent would be assumed if they completed and submitted the questionnaire. the questionnaire was administered, and data were collected using a free online tool.

Eligibility criteria:
inclusion criteria: * participants from several four-year student classes medical students were enrolled. exclusion criteria: * students who did not complete or declined to complete the questionnaire.

Keywords: career choice medical students
intestinal inflammation and carbohydrate digestion in autistic children

Conditions: Autism; Inflammation

Summary: the purpose of the study is to find correlations between non-invasive fecal tests of intestinal inflammation and macro- and microscopic evaluation of duodenal and colonic histology, disaccharidase activity, and intestinal permeability in children with autism.

gastrointestinal disorders in children with autism receive little attention. however, symptoms such as abdominal pain, diarrhea, constipation, and flatulence have been considered contributing to the behavioral problems. these symptoms are associated partially with the deficiency of enzymes digesting carbohydrates and inflammation of the gastrointestinal tract. the effect of intestinal inflammation on neurological disorders experienced by autistic children remains unclear. we will study this problem using recently developed non-invasive tests based on two proteins (calprotectin and lactoferrin) analysis in children's stool. activity of enzymes needed for carbohydrate digestion will be tested in small samples of intestinal tissue. intestinal permeability will be assessed by measuring urinary excretion of carbohydrate substances (lactulose and rhamnose) administered via the endoscope. this test will help to determine if intestinal inflammation contributes to a "leaky" gut syndrome. the study will provide valuable information for understanding the association between gastrointestinal disease and behavioral problems in autistic children.

Eligibility criteria:
inclusion criteria: * age 18 months to 17 years inclusive. * subjects referred to a massachusetts general hospital for children (mgh main campus or satellite clinic) for pediatric care or pediatric gastroenterology care. * subjects with documented gastrointestinal symptoms requiring endoscopy and duodenal pinch biopsy for disaccharidase activity evaluation for the standard medical treatment of gastrointestinal symptoms (i.e. endoscopy and biopsy cannot be performed solely for research purposes). exclusion criteria * use of any proteolytic digestive enzyme supplements: prescription or over-the-counter (e.g., pancrease \[creon-10\], lactase, etc.) up to 7 days prior to egd with biopsy. * diagnosed bleeding disorder * hypoalbuminemia * unstable respiratory status evidenced by a diagnosed respiratory condition (such as asthma) that is not adequately controlled (e.g. evidence of repeated hospitalizations for exacerbations in asthma symptoms, etc.). * unstable cardiac status evidenced by a diagnosed cardiac condition. * nasal or menstrual bleeding. additional blood in stool may effect calprotectin and lactoferrin concentration.

Keywords: autism intestine disaccharidases inflammation permeability